TGFB1 and chronic kidney disease: Losartan and TGF-β inhibitors were chosen for drug screening based on the previous studies reporting cardiovascular protective effects of angiotensin receptor blockers in CKD (Kuriyama et al., 2006; Verbeke et al., 2014; Kim-Mitsuyama et al., 2018) and our data showing the activation of intracellular TGF-β pathway in iPSC-ECs by in vitro uremic toxin mixtures.